Literature DB >> 6974957

Polymorphic acetylator phenotype and systemic lupus erythematosus.

E Johansson, K K Mustakallio, M J Mattila.   

Abstract

Out of 69 patients with spontaneous systemic lupus erythematosus (SLE), phenotyped for polymorphic acetylation with sulphadimidine, 52 (75%) were slow acetylators. In the subgroup of SLE patients with chronic biologically false positive seroreactions for syphilis the percentage of slow acetylators was even higher, 88%. In the majority of the slow acetylators the disease had started later and had followed a milder course than in rapid acetylators. Cutaneous reactions suspected to be drug-induced were seen in 19 (17 slow acetylators) during an observation period of 3--7 years. The reactions were mostly of exanthematous or urticarial type but also fixed type of eruption was seen. Provocation tests with the suspected drug were performed in 14 patients. In 5 cases it could be demonstrated that the eruption was caused by the drug. The predominance of slow acetylators among our patients with spontaneous SLE was the same as has been observed in drug-induced SLE. This suggests a similar genetic background.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6974957     DOI: 10.1111/j.0954-6820.1981.tb09799.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  3 in total

Review 1.  Systemic lupus erythematosus clinical issues.

Authors:  M B Stevens
Journal:  Springer Semin Immunopathol       Date:  1986

Review 2.  Genetically determined variability in acetylation and oxidation. Therapeutic implications.

Authors:  D W Clark
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

Review 3.  Genetic Polymorphisms and the Clinical Response to Systemic Lupus Erythematosus Treatment Towards Personalized Medicine.

Authors:  Melisa Intan Barliana; Nadiya Nurul Afifah; Riezki Amalia; Laniyati Hamijoyo; Rizky Abdulah
Journal:  Front Pharmacol       Date:  2022-03-18       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.